pharmacy compounding semaglutide news Regulator acts to close loophole enabling Australian pharmacists to make copycat Ozempic drug Drugmakers battle pharmacies over compounded

Implications for Glucagon Family Receptor Poly-Agonists: GLP-1R Agonism Is Sine Qua Non Over the past few years, novel class B1 GPCR poly-ligands, i.e., compounds that bind more than one receptor simultaneously, have joined the ranks of the classic GLP-1RAs (GLP-1R mono-agonists), such as exenatide, liraglutide, semaglutide, dulaglutide, etc

Palpitations are not commonly reported in clinical studies

Adults on GLP-1 receptor agonists for extended periods show reduced risk of cognitive decline and dementia in several observational and trial datasets, with effect sizes ranging from modest single-digit reductions to much larger ones, depending on the cohort

What are the long-term effects of Ozempic vs

Salehi M, Gastaldelli A, D'Alessio DA

IOC consensus statement on Relative Energy Deficiency in Sport (RED-S)